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Abstract
Background: The optimal stage for initiating antiretroviral therapies in HIV-1 bearing patients is
still a matter of debate.
Methods: We present computer simulations of HIV-1 infection aimed at identifying the pro et
contra of immediate as compared to deferred Highly Active Antiretroviral Therapy (HAART).
Results: Our simulations highlight that a prompt specific CD8+ cytotoxic T lymphocytes response
is detected when therapy is delayed. Compared to very early initiation of HAART, in deferred
treated patients CD8+ T cells manage to mediate the decline of viremia in a shorter time and, at
interruption of therapy, the virus experiences a stronger immune pressure. We also observe,
however, that the immunological effects of the therapy fade with time in both therapeutic regimens.
Thus, within one year from discontinuation, viral burden recovers to the value at which it would
level off in the absence of therapy.
In summary, simulations show that immediate therapy does not prolong the disease-free period
and does not confer a survival benefit when compared to treatment started during the chronic
infection phase.
Conclusion: Our conclusion is that, since there is no therapy to date that guarantees life-long
protection, deferral of therapy should be preferred in order to minimize the risk of adverse effects,
the occurrence of drug resistances and the costs of treatment.
Background
Antiretroviral therapy has significantly modified the
approach to treatment of the Human Immunodeficiency
Virus (HIV) infection. Positive effects of Higly Active
Antiretroviral Therapy (HAART) include suppression of
plasma viremia below detection level, rising circulating
CD4+ T cell count, reduction of the incidence of acquired
immunodeficiency syndrome (AIDS) and of death [1-3].
It is still unclear, however, what the "ideal moment" is for
initiating HAART. An apparent advantage of any antiretro-
viral treatment started during the early phases of HIV-1
infection (i.e., immediate or very early therapy) is to pre-
serve immune function and to reduce the risk of viral
transmission [1,4-6]. However immunological benefit
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from HAART has been shown also in asymptomatic
patients with chronic infection (i.e., deferred therapy) by
documented restoration of the naïve CD4+ T cell count
and improved antigen-specific immunity [7]. Possible
drawbacks to very early initiation of HAART, include pro-
longed exposure to antiretroviral therapy without known
clinical benefit, exposure which could result in drug toxic-
ities and development of antiretroviral drug resistance,
the need for continuous therapy with strict adherence and
associated adverse effect on quality of life and, last but not
least, increased costs [5]. The demand of new therapeutic
strategies and the urgent need to shed light on the issue of
when is the best time for initiating therapy together with
the high cost and long follow-up required by in vivo test-
ing, provide solid arguments for the use of computational
models as predictive tools.
In the present study we resorted to a computer model to
forecast the immune/viral dynamics of in silico patients
treated with HAART either in the acute phase of primary
infection or at a later date during the chronic disease. The
computational model employed closely reproduces the
hallmarks of HIV-1 infection for both drug-free (details
are described elsewhere [8]) and treated patients. We have
compared our results with a cohort of twenty-two patients
undergoing immediate therapy and used the simulator to
asses the benefits of delayed HAART initiation.
Our results suggest that deferral of HAART favors HIV spe-
cific cytotoxic T lymphocytes while minimizing toxic side-
effects, when compared to very early therapeutic interven-
tion.
Results
Subjects analysis
We started from the analysis of the cohort data of naïve
patients that received HAART (the therapeutic regimen
included protease inhibitors, nucleoside reverse tran-
scriptase inhibitors and non-nucleoside reverse tran-
scriptase inhibitors) within six months from primary
infection (i.e., including both the inflammatory phase
and after seroconversion). Table 1 reports clinical infor-
mation about the cohort data. In Table 2 patients have
been classified according to the staging method proposed
by Fiebig et al [9].
After a variable period of therapy (average: 3 ± 1 years), all
subjects were enrolled in Structured Therapy Interruption
Table 1: Subjects with an immediate treatment of acute HIV-1 infection.
ID Age Therapy† Elapsed days‡ Days on therapy At diagnosis* At first interruption
CD4 CD8 vRNA × 104 CD4 CD8 vRNA
Pt 03 19 D4T, 3TC, IDV 14 1775 653 1659 75 809 459 5794
Pt 05 40 AZT, 3TC, IDV 61 1657 444 633 100 867 476 <50
Pt 29 35 AZT, 3TC, NFV 14 1069 1103 1964 31 741 844 <50
Pt 33 19 AZT, 3TC, IDV 66 925 424 991 0.13 458 474 147
Arm A Pt 35 39 AZT, 3TC, EFV 1 1041 522 1205 78 919 607 496
Pt 37 52 AZT, 3TC, EFV 0 1371 545 1233 3.9 901 384 <50
Pt 58 26 AZT, 3TC, EFV 3 442 768 1632 50 1451 1580 <50
Pt 06 24 AZT, 3TC, IDV 32 1620 882 4146 4.1 754 726 <50
Pt 18 30 AZT, 3TC, IDV 26 635 1319 1810 15 1718 825 <80
Pt 24 34 AZT, 3TC, IDV 3 1231 507 3162 78 513 1067 <50
Pt 31 57 AZT, 3TC, EFV 19 1102 322 243 490 1154 1165 <50
Arm B Pt 41 35 AZT, 3TC, EFV 12 705 568 278 130 1326 940 <50
Pt 45 27 AZT, 3TC, EFV 5 488 307 1032 130 872 506 <50
Pt 53 27 AZT, 3TC, Lop/rit 16 503 341 779 18.9 545 529 150
Pt 04 25 AZT, 3TC, IDV 6 1561 603 1288 1.6 1047 1015 88
Pt 19 41 AZT, 3TC, IDV 13 1480 1338 716 10 1113 447 <50
Pt 28 25 AZT, 3TC, NFV 7 325 281 860 190 863 485 <80
Pt 32 36 AZT, 3TC, EFV 15 1384 409 1448 4.3 960 331 <50
Pt 72 20 AZT, 3TC, LPV 7 318 827 386 19 1005 751 <50
Pt 81 33 AZT, 3TC, NVP 33 745 412 264 32.5 522 461 68
Pt 85 27 AZT, 3TC, Lop/rit 46 717 326 669 50 855 1436 <50
Pt 92 36 3TC, Lop/rit, TNF 0 455 616 3774 46.3 1027 913 <50
Clinical information about the twenty-two patients selected at the Clinical Department of the National Institute for Infectious Disease "L. 
Spallanzani" in Rome. All subjects received HAART within six months from primary infection.
†D4T, staduvine; 3TC, lamivudine; IDV, Indinavir; AZT, Zidovudine; NFV, nelfinavir; EFV, Efavirenz; NVP, nevirapine; TNF, Tenofovir; Lop, 
lopinavir; Rit, Ritonavir. ‡ Days elapsed from diagnosis (enrollment) to initiation of HAART. *CD4 and CD8 are per microlitre of plasma, viremia is 
per millilitre of plasma.BMC Infectious Diseases 2009, 9:172 http://www.biomedcentral.com/1471-2334/9/172
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(STI). For the majority of the subjects, plasma viremia
reverts to detectable levels in a median time of ten days
following the initial HAART interruption. Despite this
rapid viral rebound, five subjects managed spontaneously
to control viremia maintaining their plasma virus load
below the detection limit for a longer time (see Figure 1
and 2). However, after 1 month, the virus was again
detectable and the patients were enrolled in STI protocols.
The CD4+ T cell response declined in absence of treatment
though remaining well above the level of 200 cells/l
defined as the onset of full-blown disease. However, with
re-institution of HAART the CD4+ T cell response rose
again. Interestingly, in all five subjects exposure to the
virus is associated with a substantial increase of the cyto-
toxic response.
In silico study of early versus deferred HAART
We used the cohort data, in particular the time window
before patients were enrolled in the STI protocol, to set the
initial conditions of the model. First of all, we performed
computer simulations in which we started a long course of
HAART (2.5 years) within six months from primary infec-
Table 2: Stages of early HIV infection.
ID HIV-RNA p24
antigenemia
HIV EIA
Ab-reactive
Wb Wb
p24
Wb
gp41
Wb
gp160
Wb
p31
Wb
p55
Wb
p66
Wb
p17
Stage
Pt 03 + + + + + + - + + V
Pt 04 + - + + + + + + + + VI
Pt 06 + + + + + + + + + VI
P t  1 8 + - + ++ + ++++ V I
Pt 19 + + + + + - V
Pt 24 + + - - II
Pt 28 + + + ind. + + IV
Pt 29 + - + + + + - + V
Pt 31 + + + ind. IV
Pt 32 + - + + + + - V
Pt 33 + + + + + - + V
Pt 35 + + ind. + + IV
Pt 37 + + + ind. IV
Pt 45 + + + + + + - V
P t  5 3 + + + ++ + ++++ V I
Pt 58 + + + + + + - + + V
Pt 72 + + ? - + + V
P t  8 1 + + ++ + + -+++ V
Pt 85 + + + - III
Patients in Table 1 classified according to the staging method in [9].
Table 2: Because data is missing, Pt 5, Pt 41 and Pt 92 are not reported in this table. Wb means Western blot pattern. Indeterminate means the 
presence of HIV-1 specific Wb bands that fail interpretative criteria for reactive Wb defined as reactivity to two of the following three bands: p24, 
gp41, gp120/160. Positive means reactive Western blot to two of the three bands: p24, gp41, gp120/160.BMC Infectious Diseases 2009, 9:172 http://www.biomedcentral.com/1471-2334/9/172
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tion (i.e., including both the inflammatory phase and
after seroconversion). Then, we fixed immunological
parameters at therapy start time on the basis of the average
values measured in in vivo patients: (5.8 ± 0.2) RNA cop-
ies/ml (in logarithmic scale), (870 ± 50) CD4 cells/l and
(430 ± 50) CD8 cells/l. Finally, the drug control effect of
HAART is to suppress viremia, during the first ten weeks,
below the detection level. This occurs in three phases with
a specific time table [10,11]. We have implemented the
model to take into account this dynamics by considering
the probability that a virus infects a cell during HAART,
follows a characteristic power low decay. The average
viremia of hundreds of silico patients has been compared
with those obtained from in vivo patients whose viral load
was known in the same time window (see Figure 3).
Due to the inability to eliminate virus infected cells,
antiretroviral treatment fails to eradicate the infection and
cessation of suppressive therapy will, most likely, be
accompanied by viral rebound. We have analyzed the
pace of viral rebound and the ability of early-treated in sil-
ico patients to spontaneously control HIV-1 replication, in
relation to the outcomes of in vivo studies. We found that
during the first month after treatment interruption,
despite viral rebound, 16% of in silico patients are able to
achieve, at least, a transient steady state off therapy, with
viral load below the limit of detection (Figure 4 panel a,
green rectangle in shadowed area). Our results are in good
agreement with cohort data that give about 22% of suc-
cessful cases of immune control (panel a, blue rectangle in
shadowed area). After that, the virus becomes sparser but
Time evolution of the virological parameters for STI subjects Figure 1
Time evolution of the virological parameters for STI subjects. Plasma viremia, CD4+ T cell and CD8 T cell response 
are plotted for three subjects of the cohort data. They were started on long courses of HAART within the first six months of 
primary infection (from left to right 3, 2 and 1.5 years, respectively). Then, they were enrolled in a structured interruption pro-
tocol (arm B). The therapy resumption was required for a viral load  50,000 copies/ml (dashed line). The shaded area indicates 
the reinstitution of therapy. They managed to control viremia after the initial treatment interruption for at least one month.BMC Infectious Diseases 2009, 9:172 http://www.biomedcentral.com/1471-2334/9/172
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still detectable and only 2% of in silico patients manage
spontaneously to control viremia six months after the ini-
tial discontinuation (shadowed area in panel b). Finally,
the virus rebounds in one year off therapy, to reach the
value at which it would level off in the absence of treat-
ment (green rectangle in panel c). These findings are con-
firmed by in vivo data in which the median viremia one
year after stopping HAART is about 10,000 RNA copies/ml
(i.e., log(RNA/ml) = 4, blue rectangles in panel c). Despite
considerable advances in the understanding of the inter-
play between HIV-1 and its host, the effect of antiretrovi-
ral treatment on the developing immune response
remains elusive. During the acute stage of HIV-1 infection
in untreated subjects, viral load expands exponentially
and antiviral immune defenses are still developing [12].
Once the HIV-specific immune response has been estab-
lished, viral load usually decreases until a viral set point is
reached. It has been shown that initiation of HAART
before the attainment of the natural equilibrium of virus
load may blunt the natural anti-HIV immune activity
[12]. We have investigated this issue and compared the
results with those obtained in silico when HAART is
delayed. In particular, in order to determine the optimal
time to initiate HAART, we performed simulations in
which we started a long course of HAART (2.5 years)
either during seroconversion (Figure 5, green lines in pan-
els a, b and c) or during the chronic stage of the disease
(red lines of the same panels). In deferred treatment, we
decided to start therapy when viral load was (4.0 ± 0.2)
copies/ml (in logarithmic scale) and the CD4+ T cell count
Time evolution of the virological parameters for unplanned therapy interruption subjects Figure 2
Time evolution of the virological parameters for unplanned therapy interruption subjects. Plasma viremia, CD4+ 
T and CD8 T cell response are plotted for two subjects of the cohort data. They were started on long courses of HAART dur-
ing the acute phase of the primary infection (from left to right 1 and 3.8 years, respectively). They then underwent unplanned 
therapy interruptions, with resumption based on medical consensus. The shaded area indicates the reinstitution of therapy. 
They controlled viremia after the initial treatment interruption for at least one month.BMC Infectious Diseases 2009, 9:172 http://www.biomedcentral.com/1471-2334/9/172
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was (400 ± 50) cells/l. Moreover, we compared CD4+ T
cell count and viremia between treated and untreated in
silico patients (blue lines in panels a, b and c).
Although the impact of a therapeutic intervention on
plasma viremia is well documented [13-15], much less is
known about the rapidity of decline with respect to timing
of therapy. Simulations reveal that with late treatment
plasma viremia declines more rapidly, approaching the
limit of detection within the first ten weeks, whereas viral
load reaches the undetectable level only after six months
when therapy is started at an early stage of disease (see Fig-
ure 3). Moreover, the virus rises more slowly in deferred
treated patients. After one year, a small percentage (1%) of
in silico patients still manage to spontaneously control
viremia, whereas the virus rebounds completely one year
after therapy discontinuation in early treated infected per-
sons (Figure 5, shadowed area in panel f). The decresing
number of in silico patients that spontaneously control
viremia, correlates in time strictly with the restoration of
the viral set point reached within one year of the termina-
tion of HAART. By that time, the efficacy of antiretroviral
drugs on viremia is almost vanished and the virus reverts
to the value at which it would level off in the absence of
treatment (blue rectangle in panel d, e and f).
The evolution of the immune response and, in particular,
the kinetics of CD4+ and CD8+ T cells in patients treated
with HAART, are subject of heated debate [12,16]. Our
results confirm the expectation that initiation of HAART
during seroconversion leads to the preservation of HIV-
specific T helper cells with the consequent maintenance of
specific immunity (Figure 5, green line panel b). In addi-
tion, we suggest that in silico patients following such an
antiviral therapy regimen show a modest loss of CD8+ T
cell numbers coincident with a decline in viremia (green
line in panel c and a). When therapy ends, the viral load
rises again within a year, but in in silico patients undergo-
ing early treatment the natural immune activity remains
impaired. It thus takes several years to restore the natural
equilibrium between the host and its uninvited guest. On
the contrary, prior to administration of HAART in chroni-
cally infected patients, HIV-1 infection is associated with
a failure in T cell homeostasis [17], resulting in a gradual
Pharmacodynamics of HIV-1 Figure 3
Pharmacodynamics of HIV-1. The effect of the antiretroviral treatment is to suppress viremia below the level of detection. 
This occurs in the first weeks after start of therapy. In particular, within two/three weeks there is an exponential decline of 
viremia of about two orders of magnitude. This rapid ablation of initial viremia reflects the decay of productively infected cells 
due to the action of reverse transcripatase inhibitors. The decline then gets slower and slower. This is mainly due to the action 
of the protease inhibitors on infected cells. Finally, the viral decline levels off, as a result of sub-optimal drug effectiveness, res-
ervoirs of virus-producing cells that are unaffected by the drug, or the emergence of resistant virus strains. Solid line repre-
sents the average behavior of hundreds in silico patients, whereas colored dots correspond to selected in vivo patients.BMC Infectious Diseases 2009, 9:172 http://www.biomedcentral.com/1471-2334/9/172
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decline in CD4+ T cell numbers (red line panel b), whereas
the cytotoxic activity is well developed (red line in panel
c). Once therapy starts, CD4+ T lymphocyte counts quickly
increase, bringing the host almost to immune restoration.
Simulation of delayed therapy produces enhancements of
both functional immune response and immune control
of infection. Our interpretation is that, during the period
prior to initiation of therapy, the virus elicits a cytotoxic
response. This, by contrast, is almost absent in early treat-
ment, as the magnitude of the infection is considerably
reduced by the action of the antiretroviral drugs.
Discussion
The timing of when antiretroviral therapy has to be initi-
ated remains a challenging issue. HAART is costly, it is
demanding for both patient and health care provider, and
it leads, quite frequently, to adverse events. The clinical
benefit of treatment must therefore be weighed against
the burden imposed by therapy on the patient and its the
side-effects. Immediate treatment has been always advo-
cated as it preserves a higher CD4+ count and prevents
potentially irreversible damage to the immune system; it
reduces the risk of HIV-associated complications [5]; it
may limit the viral dissemination, minimizing harmful
virus impact on cellular immune response. However,
long-term use of HAART is often accompanied by prob-
lems of adherence to therapy regimes, primarily in conse-
quence of intolerance to drugs and serious side effects.
Furthermore, long-term use of drugs when adherence is
poor is classically associated with the development of
viral drug resistance because of incomplete viral suppres-
Viral rebound after stopping immediate HAART Figure 4
Viral rebound after stopping immediate HAART. Percentage of patients with a given level of plasma viremia after stop-
ping HAART as results from in vivo studies (blue rectangle) and from simulations (green rectangle). The viremia has been mon-
itored in three different stages after discontinuation. From top to bottom: 1 month, 6 months and 1 year after therapy 
termination, respectively. Both in vivo and in silico patients were started on HAART during primary infection. The shadowed 
area (low viremia <50 RNA copies/ml) corresponds to the percentage of patients that manage spontaneously to control 
viremia after the initial interruption of therapy. We predict 16% of successful cases of immune control, which is in good agree-
ment with the 22% obtained by clinical observations.BMC Infectious Diseases 2009, 9:172 http://www.biomedcentral.com/1471-2334/9/172
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sion, resulting in the loss of future treatment options.
Hence, life-long treatment right from primary HIV-1
infection may not be a feasible option. In contrast, the
arguments to be considered in favor of deferred treatment
include improved quality of life; lower incidence of treat-
ment-related side effects and toxicities; reduced risk of
developing drug resistances; reduced overall time on med-
ication, as well as lower overall cost of treatment [1,5].
However, a risk in deferred HAART is that the specific T
helper cellular compartment may be already damaged
[16]. To date, clinical studies have been unable to provide
convincing data regarding the optimal timing of therapy.
In vivo studies have often been constrained by a lack of
adequate human and economic resources. Clinical trials
are demanding and require long follow-up. There is also
the difficulty of recruiting patients during the acute phase
of the infection. In this respect, a computer model may
provide a great deal of insight into the dynamics and con-
trol of HIV-infection. In particular, the use of a computer
model for the simulation of HIV-infection as a predictive
tool acquires a clinical and an epidemiological role, as it
offers the possibility to reduce the time and the costs of
Viral rebound after stopping deferred HAART Figure 5
Viral rebound after stopping deferred HAART. The drug control effect of HAART on plasma viremia is shown for 
treated subjects and compared with the viral production in absence of therapy. In the upper panel, from left to right, the viral 
load, CD4+ and CD8+ T cell count are plotted as function of years from primary HIV-1 infection. In the lower panel, the histo-
gram of the viral rebound after the first interruption of HAART is shown for three different stages (from top to bottom: 1 
month, 6 months and 1 year after therapy termination, respectively) and for in silico patients receiving either immediate (green 
histogram) or deferred therapy (red histogram). The shadowed area (low viremia <50 RNA copies/ml) corresponds to the suc-
cessful cases of immune control in drug-free period. We find that in delayed treatment 45% of in silico patients manage to spon-
taneously control viremia after the first month of therapy interruption and the virus has yet completely rebound one year after 
discontinuation, approaching the value at which it would level off in the absence of treatment (blue open rectangle).BMC Infectious Diseases 2009, 9:172 http://www.biomedcentral.com/1471-2334/9/172
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antiretroviral research, potentially leading to a reduction
in public health expenditure. The objective of the present
analysis is to gauge by means of an immune system simu-
lator the differences in the impact of long-term HAART
when initiated either in the primary or in the chronic
phase of HIV-1 infection.
There is increasing evidence that HIV-specific cytotoxic
response plays a crucial role in controlling viremia [16,18-
21]. CD8+  T cells have been thought to mediate the
decline of viremia and recent studies show that the inter-
play between viral replication and CD8+ activity influ-
ences the equilibrium viral-set-point [16].
We found that cytotoxic responsiveness declines during
long term HAART exposure in both the acute and the
chronic infection stages. However, when therapy termi-
nates, and viremia restores, in silico patients regain specific
CD8+ response. The time it takes to mount an effective
natural immune response depends on the disease's pro-
gression before therapy was initiated. Computer simula-
tions indicate that, while the immune functions are
preserved during immediate therapy, the initiation of
antiretroviral treatment before full emergence of a specific
immune response prevents cytotoxicity from developing,
whereas, in patients receiving deferred therapy, the
immune system has already mounted a specific cytotoxic
response in the phase prior to HAART, and is able to
dump viral load and to reduce virus rebound at therapy
interruption. In addition, in the presence of prompt natu-
ral immunity, the virus cannot evolve under the selective
pressure of the drug (no drug escapes are detected). This
difference fades within one year following discontinua-
tion. We therefore found no valid arguments to promote
very early therapy. Although other factors may explain the
different immunological effects of early as compared to
late initiation of HAART, our findings suggest a rationale
to support deferred therapy in clinical practice. This is in
line with an in vivo study that underlines the importance
of an effective natural host-immune response [12]. It's
reasonable to assume that viremia and CD8 are correlated
(through a non-linear relation) to CD4+ T cells since these
cells constitute both a reservoir for HIV and a stimulus for
CD8 cell proliferation. We suggest that a higher level of
CD8 in lately treated patients with respect to those who
receive early treatments is a consequence of the fact that
the immune system has spent considerable time to con-
trol viremia before HAART initiates and therefore there is
a higher level of cytotoxicity. However, in the simulations,
the difference in viremia between immediate and deferred
treated patients is very small, likewise the difference in
CTLs (~10%) and therefore it is difficult to draw final con-
clusions. In [6] the authors find a different rebound in
viremia with the early HAART controlling better the
rebound.
However, there are two major differences between the
cohorts used in [6] and in the present article: a) in the
former, patients have been recruited with a negative west-
ern blot for anti-HIV antibodies hence before seroconver-
sion while in the latter, cohort data includes patients
classified in stage IV, V and VI with respect to [9] (see
Table 2); b) in [6] patients were treated with an intensive
HAART consisting of two or three NRTIs plus a NNRTI
and a PI, whereas our patients were treated with just two
NRTI and one PI. These two features might be the cause of
a lower level of viremia at the end of HAART accounting
for a slower viral rebound in [6].
Treatment interruptions are not currently recommended
as routine clinical practice, although several strategies are
being investigated in clinical trials. The occurrence of
adverse events may, however, require cessation of therapy.
At present, a large multicentric study for the treatment of
primary HIV-1 infection is under investigation. This is
SPARTAC (Short Pulse AntiRetroviral Therapy At HIV
seroConversion), an international, randomized, control-
led trial comparing three different strategies of interven-
tion in patients recently infected with HIV-1.
The computer model used in the present analysis, the
effectiveness of which has been tested in previous studies
[8,22], may be considered as a predictive tool for other
infectious diseases and may provide useful insights in vac-
cinal models that are both time consuming and costly.
Conclusion
In conclusion, we employed a simulator of the immune
system tested against clinical data aimed at identifying the
golden moment to start the therapy. We observe that if the
therapy starts in the acute phase (stage IV-VI of [9]) then
the action of the drug impedes the immune response to
develop and, as a consequence, at the end of the therapeu-
tic period, the virus rebounds undisturbed. In contrast, if
the therapy is postponed (i.e., beyond stage VI of [9]),
then at interruption we observe a stronger immune pres-
sure. However, in both therapeutic regime the virus com-
pletely rebounds in one year off therapy. We conclude
that, given there is no therapy to date that guarantees life-
long protection, deferral of therapy should be preferred in
order to minimize the risk of adverse effects, the occur-
rence of drug resistances and the costs of treatment. Our
findings could have considerable implications on the
public health expenditure. Finally, it is worth to empha-
size that the present analysis can hold true for patients
that are diagnosticated in stage IV or beyond (i.e., more
than about 25 days from HIV exposure). Patients treated
with HAART in very early stages of the infection (stage I-
III) are likely to better control viremia after treatment
interruption [6]. As a future work we plan to verify if theBMC Infectious Diseases 2009, 9:172 http://www.biomedcentral.com/1471-2334/9/172
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computer simulations are in agreement with these find-
ings.
Methods
Criteria for diagnosis
Twenty-two patients (21 male and 1 female) with primary
HIV-1 infection were selected at the Clinical Department
of the National Institute for Infectious Disease "L. Spal-
lanzani" in Rome. Criteria for diagnosis were: docu-
mented seronegative HIV-1 antibody test within the
previous 6 months; acute symptomatic seroconversion ill-
ness; evolving HIV-specific antibody response by ELISA;
positive HIV-DNA PCR in PBMC, or positive plasma HIV-
RNA quantification in the absence of an antibody
response. Fourteen subjects were enrolled into a pilot
study of Structured Therapy Interruption (STI). Two dif-
ferent therapy interruption protocols were used: arm A
(seven patients), 4 weeks off/8 weeks on HAART; arm B
(seven patients), intermittent therapy guided by plasma
HIV-RNA levels, according with pro tempore guidelines.
Specifically, patients in arm B resumed treatment only
when necessary (plasma HIV-RNA > 50,000 copies/ml)
and stopped HAART when HIV-RNA became again unde-
tectable. This on/off treatment regime was undertaken for
the first 12 months. At this time point, all patients sus-
pended HAART and were monitored for viral and immu-
nological parameters up to month 24. Eligibility criteria
to participate in the study were as follows: CD4+ T cell
count  500 cells/l and HIV viremia in the last two years
below the detection limit, to have initiated HAART during
HIV primary infection. In addition, eight patients fol-
lowed unplanned treatment interruption mandating re-
initiation of therapy according to medical approval (see
Table 1).
The ethical committee of the institute (Clinical Depart-
ment of the National Institute for Infectious Disease "L.
Spallanzani" in Rome) approved this study and the
patients gave a written informed consent to the blood
sampling for the study.
HIV-1 RNA determination
Plasma HIV-1 RNA levels were determined by a second-
generation assay based on nucleic acid sequence based
amplification (NASBA), for samples collected until 2001
and by the branched-chain DNA assay (Versant HIV RNA
test, Version 3.0, lower limit of quantification 50 copies/
ml; Bayer Diagnostics, Milan, Italy) from 2001 until 2008.
Mathematical model
The model of immune system response we employ has
been quite extensively described in [8,22-25]. In short, it
belongs to a class of models that resort to bit strings to
represent "binding sites" of cells and molecules, as for
example lymphocyte receptors (T lymphocytes receptor
TCR, B lymphocytes receptor BCR), Major Histocompati-
bility Complexes MHC, antigen peptides and epitopes,
immunocomplexes, etc. [26]. The affinity among the dif-
ferent biological entities of the model varies according to
the Hamming distance between these bit strings, i.e.,
according to their complementarity fit. The model includes
the major classes of cells of the lymphoid lineage (T
helper lymphocytes or TH, cytotoxic T lymphocytes or
CTL, B lymphocytes and antibody-producer plasma cells,
PLB) and some of the myeloid lineage (macrophages, MA,
and dendritic cells, DC). All these entities behave as finite
state machines following a set of "rules" that describe the
different phases of the recognition and response of the
immune system against a pathogen.
The model represents a single lymph node of a vertebrate
animal that is mapped onto a three-dimensional ellipsoid
lattice with periodic boundary conditions (Figure 6). The
primary lymphoid organs thymus and bone marrow are
modelled apart: the thymus is implicitly represented by
the positive and negative selection of immature thymo-
cytes before they get into the lymphatic system, whereas
the bone marrow generates already mature B lym-
phocytes. Hence, on the lattice there are only immuno-
competent lymphocytes. In order to represent the special
features of the HIV infection, the model has been
enhanced with the description of the i) HIV replication
inside infected lymphocytes; ii)  T production impair-
ment; iii) specific response against HIV strains; iv) HIV
mutation and evolution. The evolution of HIV in
untreated patients has been studied and described by
means of this model in [27].
The virus is represented by two bit strings (each l  bits
long); the first one corresponds to the epitope (i.e., the
BCR's binding site) and the second one to the peptide
(i.e., the MHC class I and II's binding site). The simulator
allows the definition of an arbitrary number of epitopes
and peptides. In the simulations the bit string length l is
equal to 16 corresponding to a potential repertoire of
65536 distinct receptors and molecules. Actually, since
the virus is represented by one epitope and a single pep-
tide, each strain is identified by 2 l = 32 bits. So, the poten-
tial number of different virus strains becomes equal to 232.
Each time step of the simulation corresponds to eight
hours of "real life".
While the virus and the antibodies are uniquely repre-
sented (i.e., they are agents like the cells), molecules with
small molecular weight like interleukins or chemokines
are represented in terms of concentrations and their
dynamics described by the following parabolic partial dif-
ferential equations plus a degradation term accounting for
the finite half-life of molecules:BMC Infectious Diseases 2009, 9:172 http://www.biomedcentral.com/1471-2334/9/172
Page 11 of 13
(page number not for citation purposes)
where c = c(x) is the concentration of chemokines, D is the
diffusion coefficient and  is the half-life. We assume D =
3000 m2/min and  = 3 hrs [28,29]. Differences in cells
mobility are taken into account as well. TH cells are the
fastest ones, with an average velocity of 11 m/min, fol-
lowed by B cells with 6 m/min and DC with a velocity of
3 m/min [30].
Simulation of HAART
HAART is a mix of three or more powerful antiretroviral
drugs, commonly reverse transcriptase inhibitors (RTIs)
and protease inhibitors (PIs). Although most studies agree
that HAART is not able to eradicate the virus, it is very suc-
cessful in allowing the stabilization of patients' symptoms
and viremia. The simulated life cycle of the virus is repre-
sented by the following stages: 1) the virus infects CD4+ T
cells, macrophages, dendritic cells; 2) reverse transcriptase
copies the viral single stranded RNA genome into a dou-
ble-stranded viral DNA. The viral DNA is then integrated
into the host chromosomal DNA; 3) the virus remains at
rest until an event activates the transcription; 4) the repli-
cating virus buds from the cell membrane. Fully assem-
bled virions are then able to infect other cells to restart the
life cycle. HAART composed of transcriptase and protease
inhibitors influences the life cycle of the virus as follows:
RTIs block reverse transcriptase enzymatic function and
avoid completion of synthesis of the double-stranded
viral DNA thus preventing HIV-1 from replicating (i.e., it
prevents the virus in stage 1 from reaching stage 2); PIs
prevent viral replication by inhibiting the activity of HIV-
1 protease, an enzyme used by the virus to cleave nascent
proteins for final assembly of new virions (i.e., it prevents
virus assembly in stage 4). While RTI leads to cells carrying
the equivalent of the HIV-1 RNA, PI leads to "inactive"
virus which is produced in infected cells and that
accounts, among other things, for the HIV-1 DNA
observed in real life in patients during HAART. Notice that
since the clinical data available only included HIV-1 RNA
counts, as an indicator of the viral rebound we use just
HIV-1 RNA.
∂
∂
=∇−
c
t
Dc c
2 
Simulation space Figure 6
Simulation space. The space modeled consists in a 3D-ellipsoid lattice that resembles the typical shape of a lymph node. 
Each lattice point corresponds to a certain volume unit where interactions take place. Some entities are sketched: lymphocytes 
(T and B), antibodies (Ab), macrophages (MA), dendritic cells (DC) and the interleukins IL-12.BMC Infectious Diseases 2009, 9:172 http://www.biomedcentral.com/1471-2334/9/172
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We model the damage of the CD4+ T cell replenishment
due to the HIV by decreasing the physiological "normal"
cell count, whereas immune reconstitution due to the
HAART is modeled by increasing it. The parameters of this
process are set so as to reproduce, in absence of therapy, a
decrease of CD4 cell count in line with clinical expecta-
tions of time to AIDS see [8] whereas immune reconstitu-
tion due to a HAART is set to achieve an average CD4+ T
cell increase of about 200 cells/l in one year [31,32].
Simulation parameters setting
The parameters of the model can be classified in three cat-
egories: (1) unknown values (free parameters) which are
set after a tuning procedure that starts with an initial guess
and iteratively improves by looking at the outcomes that
have to reproduce the well know dynamics of HIV-1 infec-
tion (i.e., an acute phase of primary infection lasting from
three weeks to one year [33,34], an elapsed time between
infection and onset of AIDS of 7 ÷ 12 years in normal pro-
gressors [33], etc.); (2) parameters that correspond to the
initial conditions of the system and that determine the
problem under investigation (for the setting of these
parameters see the Section Results); (3) parameters whose
value is well known and available from immunology lit-
erature. An accurate description of the all parameter set-
ting is given as supplementary material (see additional file
1).
Availability and requirements
An educational version of the immune system simulator
is available on our website:
- Name: C-ImmSim
- Home page: http://www.iac.rm.cnr.it/~filippo/C-
ImmSim.html
- Operating system(s): Linux, Unix Mac OS X, Win-
dows
- Programming language: C
- Licence: C-ImmSim is available under a LICENSE
AGREEMENT that needs to be signed: http://
www.iac.rm.cnr.it/~filippo/how-to-get-
cimmsim_files/LicenseAgreement-1.pdf
List of abbreviations used
HIV: human immunodeficiency virus infection; AIDS:
acquired immune deficiency syndrome; HAART: higly
active antiretroviral therapy; STI: structured therapy inter-
ruption; PIs: protease inhibitors; RTIs: reverse tran-
scriptase inhibitors; NRTIs: nucleoside reverse
transcriptase inhibitors; NNRTIs: non-nucleoside reverse
transcriptase inhibitors; SPARTAC: short pulse antiretrovi-
ral therapy at hiv seroconversion.
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